此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项针对慢性炎症性脱髓鞘性多发性神经病 (CIDP) 受试者静脉注射 10% 人类正常免疫球蛋白 (IGIV) 的研究

2026年11月4日 更新者:Kedrion S.p.A.

一项双盲、随机、多中心研究,调查两种不同剂量静脉注射人正常免疫球蛋白 (IGIV) 10% 对慢性炎症性脱髓鞘性多发性神经病 (CIDP) 受试者的疗效和安全性

The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.

研究概览

详细说明

This is a Double Blind, Randomized study. All subjects will enter a wash-out phase of up to 12 weeks, or until functional deterioration, defined as an increase of ≥1 point (worsening) in the adjusted INCAT disability score, is demonstrated. Eligible subjects will then be randomized in a 1:2 ratio to receive either 0.5 g/kg or 1.0 g/kg KIg10 at 3-weekly intervals for 21 weeks. Subjects who relapse during randomized treatment due to functional deterioration, based on the INCAT score, will be rescued with 2.0 g/kg KIg10 at 3-weekly intervals for 21 weeks.

研究类型

介入性

注册 (估计的)

161

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Connecticut
      • Stamford、Connecticut、美国、06905
        • 招聘中
        • New England Institute for Clinical Research
        • 首席研究员:
          • Peter McAllister
    • Florida
      • Miami、Florida、美国、33155
        • 招聘中
        • Quantix Research
        • 首席研究员:
          • Sergio Jaramillo
      • Pembroke Pines、Florida、美国、33024
        • 招聘中
        • Best Choice Medical and Research Service
        • 首席研究员:
          • Vaniolky Losada Leon
      • Tampa、Florida、美国、33613
        • 招聘中
        • USF Health - Morsani Center for Advanced Healthcare
        • 首席研究员:
          • Kathleen Murray
    • New Hampshire
      • Lebanon、New Hampshire、美国、03756
        • 招聘中
        • Dartmouth-Hitchcock Medical Center
        • 首席研究员:
          • Victoria Lawson
    • Texas
      • El Paso、Texas、美国、79912
        • 招聘中
        • Advanced Neurology Epilepsy and Sleep Center/ANESC Research
        • 首席研究员:
          • Aamr Herekar

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Male or female, aged ≥18 years.

  2. Written informed consent and authorization to access personal health information obtained independently from participants indicating that they understand the purpose of, and procedures required for, the study and are willing to participate.

  3. Documented diagnosis of CIDP consistent with the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria.

  4. Current or documented history of significant disability, as defined by an overall INCAT disability score between 2 and 9. A score of 2 must be exclusively from the lower extremities.

  5. Participants are currently dependent on treatment with immunoglobulins, corticosteroids, or standard of care treatments for CIDP.

  6. Weakness of at least two limbs.

  7. Participants should be clinically stable 12 weeks prior to screening date as defined by:

    • without a worsening in INCAT score of ≥1 point, AND/OR without significant changes in clinical symptoms AND
    • without significant dose changes or requiring additional treatments.

Exclusion Criteria:

  1. Patients' incapable of giving informed consent.

  2. Pure sensory and other CIDP variants.

  3. Females who are pregnant, breastfeeding, unwilling to practice effective birth control methods as defined in Appendix C throughout the study, or planning a pregnancy during the study.

  4. IG-experienced participants requiring an IGIV dosage of more than 1.4 g/kg/month OR SCIG pre-treated participants requiring a SCIG dosage of more than 1.6 g/kg/month.

  5. Participants who have previously failed to respond to IGIV or SCIG.

  6. On screening date, a body mass index (BMI) > 35 kg/m2 or an IGIV dose that puts the patient at risk of fluid overload.

  7. CIDP and any neuropathy of other causes not consistent with the 2021 EAN/PNS criteria including:

    1. Hereditary demyelinating neuropathies, such as a hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth [CMT] disease), and hereditary sensory and autonomic neuropathies (HSANs).
    2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexopathy or neuropathy, lymphoma, and amyloidosis.
    3. Multifocal motor neuropathy (MMN).
    4. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy. Peripheral neuropathy induced by vitamin B12 deficiency.
  8. Immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with increased titers of antibodies to myelin-associated glycoprotein.

  9. Central demyelinating disorders (e.g, multiple sclerosis) or severe myopathy.

  10. Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures (e.g., severe arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy) [participants with clinically diagnosed diabetes mellitus, who have adequate glycemic control with Hemoglobin A1C (HbA1C) of <7.5% at screening, and who agree to maintain adequate glycemic control during the study are allowed].

  11. Congestive heart failure (New York Heart Association (NYHA) Class III/IV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension [i.e., diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used.

  12. History of deep vein thrombosis or thromboembolic events (e.g, cerebrovascular accident, pulmonary embolism) in the past 12 months.

  13. Condition(s) which could alter protein catabolism and/or IgG utilization (e.g, protein-losing enteropathies, nephrotic syndrome).

  14. Known history of chronic kidney disease, or glomerular filtration rate (GFR) of <60 milliliter per minute per 1.73 square meter (mL/min/1.73m2) estimated based on an established chronic kidney disease epidemiology collaboration (CKD-EPI) equation at the time of screening.

  15. Active malignancy requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.

  16. Hypersensitivity or adverse reactions (e.g, urticaria, breathing difficulty, severe hypotension, or anaphylaxis) to human blood products such as human IgG, albumin, or other blood components.

  17. Known history of immunoglobulin A (IgA) deficiency.

  18. Known history of autoimmune nodo-paranodopathies causing IG treatment resistance, including anti-neurofascin (NF) 186 antibodies and antibodies against paranodal proteins, such as NF155, contactin 1 (CNTN1), and contactin-associated protein 1 (CASPR1).

  19. Abnormal laboratory values at screening:

    1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5x upper limit of normal (ULN)
    2. Platelet count <100,000 cells/µL.
    3. Absolute neutrophil count (ANC) <1000 cells/µL.
    4. Clinically significant anemia or hemoglobin (Hgb) level of < 10.0 g/dL at screening.
  20. Ongoing/active infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV Type 1/2 infection. Participants with chronic hepatitis B or hepatitis C infection currently on treatment may participate if they have undetectable viral load within 12 months of screening date.

  21. Subjects who have received:

    1. Within 2 months before wash-out phase:

      • PE
      • change in treatment of methotrexate, azathioprine, or mycophenolate
    2. Within 3 months before wash-out phase: Efgartigimod alfa (Vyvgart)

    3. Within 5 months before wash-out phase: cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or any other immunosuppressive medications

    4. Within 12 months before wash-out phase: rituximab or alemtuzumab

  22. Participants who have received a hematopoietic stem cell transplant.

  23. Participants on corticosteroids for the treatment of CIDP after being fully washed out. Participants on maintenance doses of corticosteroid may be allowed, if treatment is for conditions unrelated to CIDP (doses usually below 20 mg/day prednisone or equivalent and where the dosage is unlikely to be tapered during the duration of the trial may be allowed for indications other than CIDP).

  24. Any disorder or condition that in the investigator's judgment may impede the participant's participation in the study, pose increased risk to the participant, or confound the results of the study.

  25. Participation in another clinical study involving an investigational medicinal product (IMP) or investigational device within 30 days prior to screening visit or within 5 half-lives of the IMP under investigation or is scheduled to participate in another clinical study involving an IMP or investigational device during the intended course of this study.

  26. History of acquired or inherited thrombophilic disorders. These will include the specific types of acquired or inherited thrombophilic disorders that could put participants at risk of developing thrombotic events. Examples include, but are not restricted to:

    1. Hereditary thrombophilia, examples include

      • Factor V Leiden mutation.
      • Prothrombin 20210A mutation.
      • Protein C deficiency.
      • Protein S deficiency.
      • Antithrombin deficiency.
    2. Acquired thrombophilias, examples include:

      • Antiphospholipid antibody syndrome.
      • Activated protein C Resistance acquired.
      • Homocysteinemia.
  27. Previous participation in this clinical study, except for participants who withdrew consent during the washout phase, prior to randomization.

  28. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:1.0 g/kg dose group for 24 weeks

This group will receive, initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion followed by 1.0 g/kg of IV KIg10 every 3 weeks.

Kedrion intravenous immunoglobulin (IVIg) 10%

其他名称:
  • 免疫球蛋白10
实验性的:0.5 g/kg dose group for 24 weeks

This group will receive, Initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion will be given followed by 0.5 g/kg of IV KIg10 every 3 weeks.

Kedrion intravenous immunoglobulin (IVIg) 10%

其他名称:
  • 免疫球蛋白10

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy of 1.0 g/kg KIg10 in the treatment of adult subjects with active CIDP
大体时间:From Baseline upto 24 weeks of treatment

The proportion of responders in the 1.0 g/kg KIg10 arm, at week 24 relative to Randomization Baseline week 0, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline.

From Baseline upto 24 weeks of treatment

次要结果测量

结果测量
措施说明
大体时间
Efficacy of 0.5 g/kg KIg10 in the treatment of adult subjects with active CIDP
大体时间:From Baseline upto 24 weeks of treatment

The proportion of responders in the 0.5 g/kg KIg10 arm at week 24 relative to randomization baseline, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline.

From Baseline upto 24 weeks of treatment
Proportion of responders (Week 24 vs Baseline) in both dose groups
大体时间:From Baseline upto 24 weeks of treatment

Proportion of responders in both dose groups based on Grip Strength and I-RODs

From Baseline upto 24 weeks of treatment
Proportion of responders in rescued subjects
大体时间:End of Treatment vs onset of rescue treatment

Proportion of responders in rescued subjects based on grip strength, I-RODS scores, adjusted INCAT disability score

End of Treatment vs onset of rescue treatment
Improvers based on the MRC-sumscore
大体时间:From Baseline upto 24 weeks of treatment

Improvers by a change of 4 points in both dose groups (week 24 versus baseline) based on MRC-sumscore

From Baseline upto 24 weeks of treatment
Mean Change in MRC-sumscore
大体时间:From Baseline upto 24 weeks of treatment

Mean change in MRC-sumscore for both dose groups at week 24 vs baseline

From Baseline upto 24 weeks of treatment
Mean Change in MRC-sumscore for rescued subjects
大体时间:End of Treatment vs onset of rescue treatment

Mean change in MRC-sumscore for rescued subjects from End of Treatment versus onset of rescue treatment

End of Treatment vs onset of rescue treatment
Disease Related QoL (CAPPRI) for each dose level
大体时间:From Baseline upto 24 weeks of treatment

For each dose level the Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) will be analysed for disease related QoL

From Baseline upto 24 weeks of treatment
Mean change in I-RODS
大体时间:From Baseline upto 24 weeks of treatment

For each dose level, mean change from randomization baseline (visit 2, week 0) to end of study (visit 10, week 24) in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score

From Baseline upto 24 weeks of treatment
Mean change in I-RODS for rescued subjects
大体时间:End of Treatment vs onset of rescue treatment

Mean change to the end of treatment assessments prior to onset of rescue treatment, in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score for rescued subjects

End of Treatment vs onset of rescue treatment

其他结果措施

结果测量
措施说明
大体时间
Number of adverse events
大体时间:From Baseline upto 25 weeks

Assess Safety and Tolerability of KIg10

From Baseline upto 25 weeks
The proportion of patients experiencing at least one adverse event.
大体时间:From Baseline upto 25 weeks

Assess Safety and Tolerability of KIg10

From Baseline upto 25 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Lakshmi Deshpande、Kedrion S.p.A.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年12月20日

研究完成 (估计的)

2027年12月27日

研究注册日期

首次提交

2024年12月16日

首先提交符合 QC 标准的

2024年12月27日

首次发布 (实际的)

2024年12月30日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Publishing of data and IPD that underlie results in the publication will be determined at study completion to comply with ICJME minimum requirements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅